Enfusion Inc [ENFN] stock is trading at $11.07, up 1.00%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ENFN shares have gain 11.37% over the last week, with a monthly amount glided 4.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman downgraded its rating to Sell on February 28, 2024, and dropped its price target to $8. On January 30, 2024, downgrade downgraded it’s rating to Underweight and revised its price target to $9 on the stock. UBS started tracking the stock assigning a Neutral rating and suggested a price target of $9 on November 07, 2023. Piper Sandler initiated its recommendation with a Neutral and recommended $11 as its price target on April 03, 2023. JP Morgan started tracking with a Neutral rating for this stock on March 15, 2023, and assigned it a price target of $12. In a note dated January 04, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $15 to $10.
Enfusion Inc [ENFN] stock has fluctuated between $7.52 and $11.38 over the past year. Enfusion Inc [NYSE: ENFN] shares were valued at $11.07 at the most recent close of the market.
Analyzing the ENFN fundamentals
Enfusion Inc [NYSE:ENFN] reported sales of 195.16M for the trailing twelve months, which represents a growth of 15.35%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.05 and Total Capital is 0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.00 points at the first support level, and at 10.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.13, and for the 2nd resistance point, it is at 11.19.
Ratios To Look Out For
For context, Enfusion Inc’s Current Ratio is 3.62. In addition, the Quick Ratio stands at 3.62 and the Cash Ratio stands at 2.05. Considering the valuation of this stock, the price to sales ratio is 7.32, the price to book ratio is 14.77 and price to earnings (TTM) ratio is 422.52.
Transactions by insiders
Recent insider trading involved Somers Deirdre, Director, that happened on Jan 13 ’25 when 1637.0 shares were sold. Director, Somers Deirdre completed a deal on Jan 13 ’25 to buy 1637.0 shares. Meanwhile, Chief Executive Officer Movchan Oleg sold 2771.0 shares on Jan 07 ’25.
